Skip to content

Efficacy and safety of iguratimod for the treatment of erosive oral lichen planus

Efficacy and safety of iguratimod for the treatment of erosive oral lichen planus

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100050748
Enrollment
Unknown
Registered
2021-09-04
Start date
2021-09-16
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oral lichen planus

Interventions

Sponsors

Peking University School and Hospital of Stomatology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years, gender is not limited; 2. Clinical and pathological diagnosis of erosive OLP, according to WHO standards; 3. Lesion area <= 3cm2; 4. Have the ability to distinguish pain.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. The lesions show abnormal proliferation; 3. Those with other confirmed oral mucosal diseases; 4. Those who have used antibiotics within 1 month and immunosuppressants within 3 months; 5. Some drugs or amalgam fillings may cause lichen-like reactions; 6. Patients with systemic diseases that seriously affect the condition of lichen planus, such as autoimmune-related diseases, diabetes, hepatitis C, tumors; 7. Those who cannot follow the doctor's orders to take medication or have incomplete records of the test process, which affects the judgment of efficacy.

Design outcomes

Primary

MeasureTime frame
lesion area;level of pain;

Countries

China

Contacts

Public ContactHua Hong

Peking University School and Hospital of Stomatology

honghua1968@aliyun.com+86 10 82195349

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026